碱性β-甘露聚糖酶基因异源表达的研究

亚克隆的碱性β-甘露聚糖酶基因(man)来源于嗜碱芽孢杆菌N16-5,构建了大肠杆菌-枯草芽孢杆菌诱导型表达质粒pDG-man,在大肠杆菌JM109中获得了活性表达,经0.5 mmol/L的IPTG诱导后,可表达5 U/mL碱性β-甘露聚糖酶。重组大肠杆菌DE3-RIL(pDG-man)表达β-甘露聚糖酶水平是大肠杆菌JM109(pDG-man)的2倍。重组枯草芽孢杆菌WB600(pDG-man)可表达19.2 U/mL碱性β-甘露聚糖酶。     

丙型肝炎病毒包膜蛋白E2可溶性单链可变区抗体在大肠杆菌中的表达

利用分子生物学技术,构建表达丙型肝炎病毒(HCV)包膜蛋白E2的人源单链可变区抗体(ScFv)的原核表达载体,并在大肠杆菌JM109中表达可溶性的HCV-E2-ScFv.以重组的HCVE2蛋白为包被抗原,利用噬菌体抗体库的表面展示技术,筛选到含有HCV-E2-ScFv基因的噬菌体克隆,从噬菌体抗体阳性克隆中提取质粒,经Ncol/NotI酶切鉴定后,该ScFv基因由750bp组成,将其亚克隆到pCANTAB5E载体中,转化大肠杆菌JM109,提取质粒进行DNA序列测定,符合ScFv的基因结构特点.IPTG诱导转化的大肠杆菌JM109,在其培养上清中获得了可溶性HCVE2单链可变区抗体的表达.酶联免疫吸附法(ELISA)证实表达的HCV-E2-ScFv具有与重组HCVE2蛋白的反应活性和特异性,对转化的JM109大肠杆菌上清中表述的HCV-E2-ScFv进行聚丙烯酰胺凝胶电泳(PAGE),证实表达的HCV-E2-ScFv的分子量为28kD.为应用HCV-E2-ScFv进行肝组织免疫组织化学和细胞内免疫基因治疗研究奠定了基础.     

人TRAIL基因原核表达载体的构建及鉴定

目的：克隆肿瘤坏死因子相关凋亡诱导配体（TRAIL）基因片段（114～281氨基酸残基）并构建原核表达载体。方法：取健康人外周血提取总RNA,设计合成引物并引入EcoR I和Xho I酶切位点,RT-PCR扩增TRAIL基因的胞外区片段,克隆入原核表达载体pGEX-6P-1中,经双酶切、PCR及测序鉴定阳性克隆。结果：从外周血cDNA中扩增出501 bp的目的片段,测序结果证实成功构建重组质粒pGEX-6P-1/TRAIL。结论：成功构建TRAIL基因的原核表达载体pGEX-6P-1/TRAIL,为肿瘤细胞的凋亡研究提供理论依据。     

青岛文昌鱼S-腺苷高半胱氨酸水解酶基因表达载体的构建及表达纯化

为了在原核细胞中表达青岛文昌鱼Branchiostoma belcheri tsingtaunese S-腺苷高半胱氨酸水解酶(S-adeno-sylhomocysteine hydrolase,SAHH),采取构建文昌鱼SAHH基因的原核表达重组质粒pGEX-6P-1-SAHH的方法,转化入大肠杆菌JMl09感受态细胞中,IPTG诱导蛋白表达,并进行分离纯化.结果经SDS-PAGE分析,重组质粒在JM109中表达并纯化得到的融合蛋白大约为70 kDa,成功构建了文昌鱼SAHH基因原核表达载体,且重组载体表达出融合蛋白,分离纯化得到目的蛋白.     

人TRAIL 基因原核表达载体的构建及鉴定

目的:克隆肿瘤坏死因子相关凋亡诱导配体(TRAIL)基因片段(114～281氨基酸残基)并构建原核表达载体。方法:取健康人外周血提取总RNA,设计合成引物并引入EcoR I和Xho I酶切位点,RT-PCR扩增TRAIL基因的胞外区片段,克隆入原核表达载体pGEX-6P-1中,经双酶切、PCR及测序鉴定阳性克隆。结果:从外周血cDNA中扩增出501 bp的目的片段,测序结果证实成功构建重组质粒pGEX-6P-1/TRAIL。结论:成功构建TRAIL基因的原核表达载体pGEX-6P-1/TRAIL,为肿瘤细胞的凋亡研究提供理论依据。     

猪防御素基因PBD-I在大肠杆菌中的重组和融合表达

用RT-PCR方法获得PBD-I基因,将该基因插入原核表达载体PinPoint^TMXa-3中,重组质粒转化大肠杆菌JM109,经IPTG诱导后以融合蛋白形式表达。SDS-PAGE电泳显示PBD-I基因在目标位置17kDa处获得了表达。PBD-I基因的成功表达为进一步研究其抗菌活性、抗菌机理及应用研究形成基础。     

一种不依赖钙离子的酸性α淀粉酶基因的克隆表达

以产酸性淀粉酶菌株Bacillus sp.CN7的基因组DNA为模板,PCR扩增到α淀粉酶成熟肽基因,将该基因插入表达质粒pSE380中,构建重组质粒pSE380-cn7a。将重组质粒导入到Escherichia coli JM109中,IPTG诱导表达。重组酶经Sephacryl S300、Ni-NTA纯化后测定其酶学性质。重组酶CN7A的最适温度为65°C,最适pH为5.5?6.0,对可溶性淀粉的Km值为3.784g/L,最大反应速度为101.2mg/(L·min),该酶的热稳定性不依赖钙离子。     

轮状病毒vp8基因在原核系统中的初步表达

通过RT-PCR反应获得轮状病毒Wa株 vp8基因的cDNA片段,将其克隆入pGEX-5X-1表达载体中,构建重组质粒pGEX-VP8,转化大肠杆菌JM109,筛选阳性克隆子并对插入片段vp8进行序列测定,诱导后通过SDS-PAGE检测重组蛋白,并观察表达量随时间变化的特征.结果显示,测序结果与vp8序列一致,VP8蛋白的表达量在诱导后6-8h达到高峰.     

肿瘤坏死因子相关凋亡诱导配体的表达及其活性检测

目的:构建肿瘤坏死因子相关凋亡诱导配体(TRAIL)高表达工程菌株,以获得具有生物学活性的重组TRAIL蛋白.方法:合成TRAIL基因,转到大肠杆菌中,IPTG诱导获得成功表达;进一步优化,增加可溶形式的蛋白质.利用硫酸铵对发酵液进行沉淀,经Ni柱、阴离子和阳离子交换柱层析,最终获得蛋白质纯品,对其进行体外活性检测.结果:经过IPTG诱导后,TRAIL达到菌体总蛋白的30％;经过优化,可溶形式蛋白达到55％.纯化获得纯度高于95％的TRAIL样品,体外测活结果表明:TRAIL蛋白能有效抑制多种肿瘤细胞增殖,抑制率达到70％-92％.结论:重组TRAIL以可溶形式得到高效表达,且具有较好的生物学活性,为其开发成药用蛋白奠定基础.     

重组幽门螺杆菌ureA,ureB低温表达、纯化及抗原鉴定

目的：建立经济有效的方法,从大肠杆菌表达,纯化重组幽门螺杆菌尿素酶A、B亚单位。方法：含重组表达质粒pGEX-2T/ureA,pGEX-2T/ureB大肠杆菌分别在不同浓度IPTG、不同温度条件下作诱导培养,以SDS-PAGE分析表达产物,采用谷胱甘肽-Sepharose 4B亲和层分离纯化表达产物,以Western-blotting和ELISA对纯化产物作抗原性分析鉴定。结果：IPTG诱导浓度为0.1mmol/L;诱导温度为28℃,含重组质粒大肠杆菌表达可溶性融合蛋白GST-ureA、GST-ureB各约占总表达产物的78%和87%,经亲和层析,得纯度90%以上的GST-ureA约为14mg/L。GST-ureB约为18mg/L;融合蛋白呈ureA、ureB抗原性反应。结论：建立了低温诱导及纯化高纯度ureA、ureB基因表达产物的方法,所得纯化产物具有ureA、ureB抗原活性,为进一步的应用研究打下基础。     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

Synthesis and antimicrobial studies of hydrazone derivatives of 4-[3-(2,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(3,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid

Microbial resistance to antibiotics is an unresolved global concern, which needs urgent and coordinated action. One of the guidelines of the Centers for Disease Control and Preventions (CDC) to combat antibiotic resistance is the development of new antibiotics to treat drug-resistant bacteria. In our effort to find new antibiotics, we report the synthesis and antimicrobial studies of 30 new pyrazole derivatives. These novel molecules have been synthesized by using readily available starting materials and benign reaction conditions. Some of these molecules have shown activity with MIC values as low as 0.78?µg/mL against four bacterial strains; Staphylococcus aureus, methicillin-resistant S. aureus, Bacillus subtilis, and Acinetobacter baumannii. Furthermore, active molecules are non-toxic to mammalian cell line.

     

Comparative morphology of the carpel in the Liliaceae: Hewardieae, Petrosavieae, and Tricyrteae

The young pistils in the melanthioid tribes, Hewardieae, Petrosavieae and Tricyrteae, are uniformly tricarpellate and syncarpous. They lack raphide idioblasts. All are multiovulate, with bitegmic ovules. The Petrosavieae are marked by the presence of septal glands and incomplete syncarpy. Tepals and stamens adhere to the ovary in the Hewardieae and the Petrosavieae but not in the Tricyrteae. Two vascular bundles occur in the stamens of the Hewartlieae and Tricyrtis latifolia. Ventral bundles in the upper part of the ovary of the Hewardieae are continuous with compound septal bundles and placental bundles in the lower part. Putative ventral bundles occur in the alternate position in the Tricyrteae and putative placental bundles in the opposite. position in the Petrosavieae. The dichtomously branched stigma in each carpel of the Tricyrteae is supplied by a bifurcated dorsal bundle.     

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226).